-
-
-
-
-
-
-
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
-
-
-
-
-
-
-
MIAX sells 90% of derivatives exchange to Robinhood-Susquehanna venture
-
-
-
-
-
-
-
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
-
-
-
-
-
-
-
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
-
-
-
-
-
-
-
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights
-
-
-
-
-
-
-
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
-
-
-
-
-
-
-
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
-
1,199,832 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

